ReviewResearch (Washington, D.C.)2026
DNA Nanotechnology-Enabled Precise Regulation of Nanozymes and Their Applications.
Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes overcome key limitations of natural enzymes, including poor environmental tolerance, high production costs, and batch-to-batch variability, with their enhanced physicochemical stability and controllable catalytic performance, thus enabling applications in biocatalysis and disease theranostics. However, their practical applications remain limited by insufficient catalytic efficiency, inadequate target specificity, and restricted programmable dynamic adaptability. DNA nanotechnology offers a versatile and biocompatible framework for the precise regulation of nanozymes due to its sequence-defined programmability and precise molecular recognition capability. This approach improves catalytic performance while maintaining excellent biocompatibility and low immunogenicity. This review systematically summarizes the latest advances in DNA nanotechnology-mediated precise regulation of nanozymes, with particular emphasis on the mechanistic basis of 6 regulatory modes. We further examine the representative applications of these DNA-nanozyme hybrid systems in disease therapy, biomedical sensing, and environmental monitoring, and outline the key challenges and future directions toward clinical and industrial translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.